Catalyst
Slingshot members are tracking this event:
European Commission Approves Bristol-Myers Squibb’s ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Additional Information
ORENCIA is the first biologic therapy with an EU indication specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive diseaseThis approval marks the first time that MRI assessment of structural and inflammatory measures of disease severity are cited in SmPC to support an RA indication
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Orencia, Abatacept, Progressive Disease, Rheumatoid Arthritis, Mehotrexate
